Cargando…
Health Technology Assessment of Advanced Therapy Medicinal Products: Comparison Among 3 European Countries
Even for centrally approved products, each European country is responsible for the effective national market access. This step can result in inequalities in terms of access, due to different opinions about the therapeutic value assessed by health technology assessment (HTA) bodies. Advanced therapy...
Autores principales: | Gozzo, Lucia, Romano, Giovanni Luca, Romano, Francesca, Brancati, Serena, Longo, Laura, Vitale, Daniela Cristina, Drago, Filippo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531540/ https://www.ncbi.nlm.nih.gov/pubmed/34690785 http://dx.doi.org/10.3389/fphar.2021.755052 |
Ejemplares similares
-
The therapeutic value of treatment for multiple sclerosis: analysis of health technology assessments of three European countries
por: Gozzo, Lucia, et al.
Publicado: (2023) -
Access to Innovative Neurological Drugs in Europe: Alignment of Health Technology Assessments Among Three European Countries
por: Gozzo, Lucia, et al.
Publicado: (2022) -
The Regulatory Challenges for Drug Repurposing During the Covid-19 Pandemic: The Italian Experience
por: Gozzo, Lucia, et al.
Publicado: (2020) -
Dexamethasone Treatment for Covid-19, a Curious Precedent Highlighting a Regulatory Gap
por: Gozzo, Lucia, et al.
Publicado: (2020) -
Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?
por: Brancati, Serena, et al.
Publicado: (2021)